Impel Pharmaceuticals Inc.

Impel Neuropharma, Inc.

Kelsey H Satterly

John D Hoekman

Aditya R Das

Inna Dashevsky

Stephen B Shrewsbury

Bhavin Y Gajera

Gregory J Davies

Scott Youmans

Christopher William Fuller

Scott B Youmans

Christopher Fuller

Methods are provided for acute treatment of agitation, including agitation in patients with schizophrenia or bipolar disorder, comprising administering to a subject with agitation an effective dose of a dry pharmaceutical composition comprising olanzapine, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma olanzapine concentration (C) of at least 30 ng/mL, with (b) a mean time to C(T) of olanzapine of less than 0.5 hours. Dry pharmaceutical compositions and devices suitable for intranasal delivery of olanzapine are provided.

Intranasal delivery of olanzapine by precision olfactory device

A dry pharmaceutical composition is provided that is suitable for respiratory tract delivery of levodopa and DDI for treatment of Parkinson's disease or Parkinson syndrome. The dry pharmaceutical composition comprises levodopa, a dopa decarboxylase inhibitor (DDI) and at least one excipient. A unit dosage form of the dry pharmaceutical composition and a method of treating a patient with Parkinson's disease or Parkinson syndrome by administering the dry pharmaceutical composition are also provided.

Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's disease

Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's Disease

Methods are provided for acutely treating migraine headache with or without aura. The methods comprise administering to a subject with migraine headache an effective dose of a liquid pharmaceutical composition comprising dihydroergotamine (DHE) or a salt thereof, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma DHE concentration (C) of at least 750 pg/ml, (b) with a mean time to C(T) of DHE of less than 45 minutes, and (c) a mean plasma AUCof DHE of at least 2500 pg*hr/ml. Also provided are kits for acutely treating migraine with or without aura in which a liquid pharmaceutical composition comprising DHE or DHE salt is contained within a sealed vial that is attachable to a precision intranasal olfactory delivery device packaged therewith.

Intranasal delivery of dihydroergotamine by precision olfactory device

Growing community of inventors

Seattle, WA, United States of America

Kelsey H Satterly